#USA #Cambridge #biotechnology #CAR-T therapy #CREATE Medicines

CREATE Medicines Achieves Milestone in CAR-T Therapy

In a remarkable advancement in the realm of biotechnology, CREATE Medicines, Inc. has announced the successful demonstration of complete B cell depletion using its innovative in vivo CAR-T platform in non-human primates (NHP). This milestone not only highlights the firm's pioneering efforts but also underscores the potential for transformative treatments in oncology and autoimmune disorders. The results of this significant study are set to be presented at the prestigious Keystone Symposia Emerging Cell Therapies conference, taking place from February 1-4 in Banff, Alberta.

Details of the Research

The results of CREATE's extensive research reveal a robust capability for creating a differentiated receptor design alongside a targeted RNA-lipid nanoparticle (LNP) platform that supports repeatable dosing. The company's Chief Scientific Officer, Robert Hofmeister, PhD, expressed optimism regarding the platform's extensive potential, noting, "The broad potential of our platform across oncology and autoimmune is now validated in both humans and NHPs."

Key Highlights

1. Complete B Cell Depletion: The study successfully illustrated the ability to achieve complete B cell depletion in non-human primates.
2. Next-Generation CAR Technology: Utilizing a next-generation T cell receptor-specific CAR and the conventional 41BBζ CAR allowed this remarkable outcome, positioning CREATE's approach as a leader in CAR therapy innovation.
3. Modular RNA-LNP Delivery: The RNA-LNP delivery system enables flexible configurations of CAR deployment, ensuring targeted immune cell programming within living organisms.
4. Tailored Immune Activation: The receptor architecture is adaptable, facilitating custom immune activation, persistence, and control across diverse medical applications.

Addressing Limitations of Current Therapies

CREATE's in vivo CAR-T platform is devised to tackle the principal challenges associated with ex vivo cell therapies, such as the complexity of cell harvesting, manipulation, and conditioning. Unlike traditional methods, this innovative platform enables CARs to integrate directly into the T cell receptor, allowing for precise immune programming and mitigating the risk of off-target effects. This aspect is crucial, particularly for CREATE's multi-immune programs, where careful control and selective functionality are paramount.

Presentation Details at Keystone Symposia

• - Date and Time: February 2nd, 7:30 PM MST
• - Location: Fairmont Banff Springs, Banff, Alberta, Canada
• - Poster Number: 1533
• - Poster Title: In Vivo Generation of CAR-T Cells for the Treatment of B Cell Mediated Autoimmunity and Hematological Malignancies
• - Program Link: Keystone Symposia Conference Program

About CREATE Medicines

CREATE Medicines stands at the forefront of biotechnology with groundbreaking advancements in in vivo CAR therapy. Their proprietary mRNA-LNP platform effectively programs immune cells directly within the body, paving the way for scalable and repeatable off-the-shelf immunotherapies. With proven clinical validation and a developing pipeline focused on both cancer and autoimmune disorders, CREATE is set to revolutionize therapeutic options in the field of immunotherapy. For further information, visit their website at createmedicines.com. Additionally, you can follow them on LinkedIn and X (formerly Twitter) for updates and insights.

• ---

By redefining the boundaries of CAR-T therapy, CREATE Medicines is not just fostering innovation in biotechnology but is poised to enhance patient outcomes across various medical domains. The future of in vivo CAR therapies looks promising, with CREATE leading the charge towards safer, more effective treatments.